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Under an ideal implementation of Model for End-Stage Liver Disease (MELD)–based liver allocation, the only factors that
would predict deceased donor liver transplantation (DDLT) rates would be the MELD score, blood type, and donation
service area (DSA). We aimed to determine whether additional factors are associated with DDLT rates in actual practice.
Data from the Scientific Registry of Transplant Recipients for all adult candidates wait-listed between March 1, 2002 and
December 31, 2008 (n ¼ 57,503) were analyzed. Status 1 candidates were excluded. Cox regression was used to model
covariate-adjusted DDLT rates, which were stratified by the DSA, blood type, liver-intestine policy, and allocation MELD
score. Inactive time on the wait list was not modeled, so the computed DDLT hazard ratios (HRs) were interpreted as
active wait-list candidates. Many factors, including the candidate’s age, sex, diagnosis, hospitalization status, and height,
prior DDLT, and combined listing for liver-kidney or liver-intestine transplantation, were significantly associated with DDLT
rates. Factors associated with significantly lower covariate-adjusted DDLT rates were a higher serum creatinine level (HR
¼ 0.92, P < 0.001), a higher bilirubin level (HR ¼ 0.99, P ¼ 0.001), and the receipt of dialysis (HR ¼ 0.83, P < 0.001).
Mild ascites (HR ¼ 1.15, P < 0.001) and hepatic encephalopathy (grade 1 or 2, HR ¼ 1.05, P ¼ 0.02; grade 3 or 4,
HR ¼ 1.10, P ¼ 0.01) were associated with significantly higher adjusted DDLT rates. In conclusion, adjusted DDLT rates
for actively listed candidates are affected by many factors aside from those integral to the allocation system; these factors
include the components of the MELD score itself as well as candidate factors that were considered but were deliberately
omitted from the MELD score in order to keep it objective. These results raise the question whether additional candidate
characteristics should be explicitly incorporated into the prioritization of wait-list candidates because such factors
are already systematically affecting DDLT rates under the current allocation system. Liver Transpl 18:1456-1463,
2012. VC 2012 AASLD.
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The Model for End-Stage Liver Disease (MELD) score
is the unit of allocation and the donation service area
(DSA) is the unit of distribution for deceased donor
livers among candidates with chronic liver disease
who are listed for deceased donor liver transplanta-
tion (DDLT) in the United States.1
The MELD score was adopted in February 2002 as
the basis for prioritizing candidates with end-stage
liver disease awaiting DDLT. The intention was to
reduce wait-list mortality through the offering of
DDLT according to the severity of liver disease, the
minimization of geographic disparities, and the de-
Abbreviations: DDLT, deceased donor liver transplantation; DSA, donation service area; HCC, hepatocellular carcinoma; HR,
hazard ratio; ICU, intensive care unit; INR, international normalized ratio; MELD, Model for End-Stage Liver Disease; SRTR,
Scientific Registry of Transplant Recipients; SSDMF, Social Security Death Master File; TCR, transplant candidate registration;
TRR, transplant recipient registration.
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emphasis of waiting times.2,3 The MELD score is a
well-validated measure of the wait-list mortality risk
(ie, the severity of liver disease).4,5 In contrast to the
Child-Turcotte-Pugh score, which includes 2 subjec-
tive components (ascites and hepatic encephalop-
athy), the MELD score is calculated quantitatively
with laboratory values: the total bilirubin level, the
international normalized ratio (INR) of the prothrom-
bin time, and the serum creatinine level.5 Candidates
are offered deceased donor livers only if they are listed
as active on the wait list.
A DSA is a distinct, nonoverlapping geographic area
served by 1 of the 58 federally certified organ procure-
ment organizations. DSAs may include 1 or more
transplant programs for a given organ and 1 or more
donor hospitals. DSAs are currently the primary units
of distribution for deceased donor livers to candidates
with chronic liver disease.
In a frictionless system, the DSA, an active status,
and the MELD score would be the only factors pre-
dicting DDLT rates for blood group types. However,
recent studies have shown that female sex is associ-
ated with a lower DDLT.6-9 Hispanics have an 8%
lower DDLT rate in comparison with whites, and
Asians with MELD scores of 30 to 40 have a 46%
lower DDLT rate than whites with comparable disease
severity.8-10 The objective of the current study was to
identify other candidate factors that influence DDLT
rates for wait-listed candidates in the United States.
PATIENTS AND METHODS
Patient Population and Cohort
This study was based on data obtained from the Sci-
entific Registry of Transplant Recipients (SRTR) and
the Social Security Death Master File (SSDMF).11 The
SRTR maintains a database of all candidates for and
recipients of solid organ transplants in the United
States. Candidates on waiting lists for organ trans-
plantation and candidates who receive organ trans-
plants are tracked on a periodic basis with the use of
data collection forms completed by organ transplant
programs and submitted to the Organ Procurement
and Transplantation Network. The SRTR database
has a uniform structure based on mandatory trans-
plant candidate registration (TCR) information pro-
vided by the transplant program at the time of place-
ment on the wait list (through a TCR form). Online
status updates are required for MELD scores and
other clinical measures while a candidate is wait-
listed, and information is provided by the transplant
program at the time of DDLT [through transplant re-
cipient registration (TRR)]. Transplant follow-up infor-
mation is required 6 months after transplantation, 1
year after transplantation, and yearly thereafter
(through a transplant follow-up form). These data, in
addition to data from the Organ Procurement and
Transplantation Network regarding candidates on the
waiting list and the allocation of organs, are included
in the SRTR database.
The SRTR supplements information on vital status
with data on deaths from the SSDMF. Data collection
by the SRTR is exempt from oversight under the
public benefit or service program provisions of the
Code of Federal Regulations (45 CFR 46.101[b][5]), as
approved by the institutional review board of the Health
Resources and Services Administration of the Depart-
ment of Health and Human Services. The SSDMF
includes updated information on all participants in the
Social Security system. Information on deaths reported
to the Social Security system for the administration of
the death, disability, and retirement benefit programs
is kept in the SSDMF database.
The study population included all candidates  18
years old who were listed for DDLT between March 1,
2002 and December 31, 2008 (n ¼ 57,503). Status 1
candidates were excluded. Data on each candidate
were collected from TCR and TRR forms as well as
status update files. Data from the SSDMF were used
to ascertain deaths while patients were on the waiting
list or after their removal.
Statistical Approach
For descriptive analyses, continuous variables were
expressed as medians and interquartile ranges; cate-
gorical variables were expressed as percentages. Asci-
tes was reported as none, mild, or moderate to severe;
hepatic encephalopathy was reported as none, grade
1 or 2, or grade 3 or 4 on the TCR form and was
updated on the TRR form for each candidate. The
wait-list data for all variables was complete except for
hospitalization status (6% missing data) and serum
sodium (38% missing data). The mandatory sub-
mission of serum sodium data along with MELD
covariates went into effect on November 1, 2004.
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Candidates listed and undergoing transplantation
before November 1, 2004 accounted for the missing
serum sodium data.
The primary outcome of interest was the receipt of
DDLT. Unadjusted DDLT rates were calculated
through the division of the number of DDLT proce-
dures by the aggregate patient-years at risk (active on
the waiting list), and they were expressed as trans-
plants per 1000 patient-years. For each candidate,
the time at risk began on the date of wait listing and
ended at the earliest of the following: the receipt of
DDLT, the end of the study’s observation period
(December 31, 2008), the granting of an exception
score, or death. Because dead candidates cannot
undergo DDLT, pertinent follow-up for such candi-
dates ceased at the time of death. Our primary objec-
tive was to model DDLT rates, and candidates can
undergo DDLT only while they are listed as active;
therefore, only the active wait-list time was modeled,
so the covariate-adjusted DDLT hazard ratios (HRs)
were interpreted as being for active wait-list candi-
dates, all other factors being equal.
The regression modeling was split into separate
stages, each requiring different Cox models. First, to
delineate the effects of candidate factors on DDLT
rates at a given MELD score, in a given DSA, and
among active candidates, we fitted a time-dependent
Cox regression model of covariate-adjusted DDLT
rates. This model was stratified by the DSA, blood
type, liver-intestine policy, and allocation MELD
score, with the latter two coded as time-dependent
covariates. The allocation MELD score refers to the
MELD score at which an actively listed candidate is
allocated a deceased donor liver. Starting in March
2005, the liver-intestine policy refers to the additional
10 points given to candidates on both the liver and
intestine wait lists.1 The model included terms for se-
rum creatinine, bilirubin, dialysis, and serum sodium;
a candidate’s age, sex, race/ethnicity, diagnosis,
height, weight, and history of diabetes; ascites; he-
patic encephalopathy; hospitalization status; albu-
min; listing for combined liver-kidney transplantation
and listing for combined liver-intestine transplanta-
tion; and a history of previous DDLT. The model also
included interactions between age and hospitalization
status, female sex and height, female sex and creati-
nine, and creatinine and height.
Second, to quantify the effects of the MELD score
on DDLT rates, we fitted a separate covariate-
adjusted, time-dependent Cox regression model strati-
fied by the DSA, blood type, and liver-intestine policy.
Instead of stratification by the MELD score, the MELD
score was included in the model as a set of categorical
covariates (1 per MELD score).12 The goal of this
model was to assess the degree to which DDLT rates
are monotone with respect to the MELD score.
The third Cox regression model was stratified by the
individual MELD score (ie, in addition to the DSA,
blood type, and intestine listing policy). Because the
model was stratified by the MELD score, we could not
directly estimate its effect on DDLT rates. However,
the purpose of this component of the analysis was to
estimate the impact of the remaining covariates. After
fitting this third model, we calculated each candidate’s
HR with the model covariates (which excluded those for
which adjustments were made through stratification).
We then divided each candidate-specific HR by its re-
spective MELD score–specific mean so that the scaled
candidate-specific HRs would average to 1 within each
MELD score. We then examined box-whisker plots for
each MELD score. The variability within each MELD
score–specific distribution of HRs reflected the system-
atic heterogeneity in DDLT rates (due to the impact of
age, sex, race/ethnicity, diagnosis, height, weight, a
history of diabetes, ascites, encephalopathy, diabetes,
hospitalization status, serum sodium, albumin, com-
bined liver-kidney listing, combined liver-intestine list-
ing, and a history of previous DDLT). The results were
interpreted as being for candidates with the same
MELD score and were adjusted for the DSA, blood type,
and liver-intestine policy.
TABLE 1. Baseline Characteristics of the Cohort at
Listing (n 5 57,503)
Variable Value










Hepatitis C (%) 33
HCC (%) 17
Weight (kg)* 82 (70-95)
Height (cm)* 173 (165-180)
Serum creatinine (mg/dL)* 1.0 (0.8-1.3)
Dialysis (%) 4
Serum bilirubin (mg/dL)* 2.2 (1.3-4.4)
INR* 1.4 (1.2-1.6)




Grade 1 or 2 57
Grade 3 or 4 5
Previous liver transplantation (%) 6
Hospitalization in ICU (%) 4






Combined liver-intestine listing (%) 0.5
Combined liver-kidney listing (%) 6
*The data are presented as medians and interquartile
ranges.
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All statistical analyses were conducted with SAS 9.2
(SAS Institute, Cary, NC).
RESULTS
Baseline Characteristics of the Cohort at
Listing
The characteristics of the 57,503 candidates at listing
are shown in Table 1. The median age of the cohort
was 53 years; 66% were male; and 72% were Cauca-
sian, 8% were African American, 14% were Hispanic,
5% were Asian American, and less than 1% were of
another race or ethnicity. Twenty-two percent of the
candidates did not have ascites, 53% had mild asci-
tes, and 25% had moderate to severe ascites at listing.
Sixty-two percent had hepatic encephalopathy; 5%
had grade 3 or 4 hepatic encephalopathy. The median
serum bilirubin, serum creatinine, INR, and serum
sodium levels were 2.2 mg/dL, 1.0 mg/dL, 1.4, and
137 mmol/L, respectively. At listing, 4% of the candi-
dates were on dialysis, and 9% had serum sodium
levels  131 mmol/L.
Unadjusted DDLT Rates Among Active
Candidates
During the study period, there were 57,503 active
wait-list candidates, and DDLT was performed 21,730
times. The characteristics of the DDLT recipients
are listed in Table 2. The median time to DDLT for
recipients was 67 days. The overall unadjusted
DDLT incidence rate was 415 transplants per 1000
patient-years.
Factors Other Than the MELD Score, DSA, and
Blood Type Associated With Significantly
Higher or Lower DDLT Rates
The top half of Table 2 shows the main effects associ-
ated with higher DDLT rates. Every 5-year increase in
the candidate’s age was associated with a 2% higher
DDLT rate. Candidate characteristics such as hepati-
tis C, hepatocellular carcinoma (HCC), hepatic ence-
phalopathy, and mild ascites were independently
associated with significantly higher DDLT rates. Can-
didates who were hospitalized [whether in the inten-
sive care unit (ICU) or not] had a higher DDLT rate
than nonhospitalized candidates. Each 10-cm
increase in height was associated with a 3% higher
DDLT rate (HR ¼ 1.03, P ¼ 0.005). Listing for com-
bined liver-kidney transplantation and combined
liver-intestine transplantation was associated with
79% and 90% higher DDLT rates, respectively.
Candidate factors associated with lower DDLT rates
are shown in the bottom half of Table 2. DDLT rates
were 17% lower for females versus males. Prior DDLT
TABLE 2. Candidate Factors Significantly Associated With DDLT Rates
Factors Associated With Higher Rates HR P Value
Median or % for
Transplant Patients
Age at liver transplantation
(per 5-year increase)
1.02 0.001 53 years
Height (per 10-cm increase) 1.03 0.005 173 cm
Hepatitis C (versus all others) 1.07 <0.001 39%
HCC (versus all others) 1.26 <0.001 5%
Grade 1 or 2 hepatic encephalopathy
(versus none)
1.05 0.02 64%
Grade 3 or 4 hepatic encephalopathy
(versus none)
1.10 0.01 12%
Mild ascites (versus none)* 1.15 <0.001 54%
Hospitalization (versus no hospitalization)
In ICU 1.19 <0.001 6%
Not in ICU 1.15 <0.001 16%
Combined liver-intestine listing 1.79 <0.001 0.7%
Combined liver-kidney listing 1.90 <0.001 9%
Factors Associated With Lower Rates HR P Value
Median or % for
Transplant Patients
Female (versus male) 0.83 <0.001 32%
Serum creatinine (per 1 mg/dL increase) 0.92 <0.001 1.3 mg/dL
Dialysis (versus no dialysis) 0.83 <0.001 11%
Bilirubin (per 1 mg/dL increase) 0.996 0.001 5.1 mg/dL
History of previous liver transplantation
(versus none)
0.69 <0.001 8%
*Moderate to severe ascites was not significant.
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and higher bilirubin levels were also associated with
significantly lower DDLT rates. Each unit increase
in serum creatinine and the receipt of dialysis were
associated with 8% and 17% lower DDLT rates,
respectively.
In a supplementary analysis, the interaction
between height and creatinine was also found to be
significant (HR ¼ 1.001, P ¼ 0.03). This suggested
that the DDLT rate was lower for shorter candidates
than taller candidates at a given creatinine level and
at a given MELD score. Interactions between age
and hospitalization in the ICU (P ¼ 0.23), between age
and hospitalization not in the ICU (P ¼ 0.78), between
female sex and creatinine (P ¼ 0.90), and between
female sex and height (P ¼ 0.23) were not significant.
Race/ethnicity did not affect the DDLT rates.
Association of the MELD Score and Other
Factors With DDLT Rates
Figure 1 depicts the effect of the MELD score (ie, the
current allocation MELD score) on DDLT rates. The
MELD score was used as a time-dependent covariate
such that the fitted model incorporated changes in
each candidate’s MELD score during the follow-up pe-
riod. A MELD score of 15 served as the reference
score and hence had an HR set equal to 1 (log HR ¼
0). As expected, higher MELD scores tended to be
associated with higher covariate-adjusted DDLT rates.
Figure 1 confirms that the DDLT rates increased
strongly with increasing MELD scores, as would be
expected. However, certain traits of this plot are note-
worthy. First, candidates with a MELD score of 6 had
a higher transplant rate than candidates with a
MELD score of 7, 8, 9, or 10. In fact, DDLT rates
actually decreased across the MELD score range of
6 to 8. Between a MELD score of 9 and a MELD score
of 27, the DDLT rates increased nearly monotonically,
as expected, and this continued up to a MELD score
of 32. Although the DDLT rate was highest for candi-
dates with a MELD score of 40, the DDLT rates were
fairly similar for patients with MELD scores of 32 to
40. Figure 2 shows the variability in DDLT rates
within each given allocation MELD score, with adjust-
ments for the DSA, blood type, and liver-intestine pol-
icy. For each MELD score, the box represents the
75th and 25th percentiles, and the whiskers denote
the 95th and 5th percentiles. The horizontal line
within each box denotes the median, which was very
close to 1 in each case; this was a result of scaling the
HRs within each MELD score to have a mean of 1.0.
Approximately 50% of the distribution of HRs was
within the 0.9 to 1.1 interval, and this meant that at a
given MELD score, half of the candidates were within
10% of the average predicted DDLT rate. However, an
examination of the whiskers revealed that at most
MELD scores, approximately 10% of the candidates
were 30% away from the MELD score–specific aver-
age (ie, the HR was either < 0.7 or >1.3).
A re-examination of Fig. 2 shows that if the MELD
score were actually the only factor (other than the
DSA, blood type, and liver-intestine policy) to affect
DDLT rates, there would be no distribution of HRs; at
a given MELD score, each candidate would have the
same predicted DDLT rate, which after scaling would
equal 1. The whiskers for each MELD score–specific
distribution of HRs reflects the systematic heterogene-
ity in DDLT rates (due to the impact of age, sex, diag-
nosis, height, weight, a history of diabetes, ascites,
encephalopathy, diabetes, hospitalization status,
serum sodium, albumin, interaction between height
and creatinine, listing for combined liver-kidney
Figure 1. Effect of the allocation
MELD score (per single level
change) on the DDLT rate. MELD
score–specific HRs were estimated
with a model stratified by the
DSA, blood type, and intestine
listing policy. Each score was
compared to the reference MELD
score of 15 (HR ¼ 1).
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transplantation, listing for combined liver-intestine
transplantation, and a history of previous DDLT). The
variation in Fig. 2 reveals, for example, that candi-
dates may have a predicted DDLT rate that is 30%
greater or 30% less than their respective MELD score–
specific average because of the combination of their
adjustment covariate profile, as described previously
(ie, age, sex, diagnosis, height, weight, a history of di-
abetes, ascites, encephalopathy, hospitalization sta-
tus, serum sodium, albumin, listing for combined
liver-kidney transplantation, listing for combined
liver-intestine transplantation, and a history of previ-
ous DDLT).
DISCUSSION
Our study has identified the important candidate fac-
tors—poor renal function, dialysis, poor liver function,
and a history of previous liver transplantation—that
negatively affect DDLT rates in actual clinical practice
for wait-listed candidates. We have also validated a
previously identified factor, female sex, as an impor-
tant determinant of DDLT rates. In addition, our
study has found that some new candidate factors
such as age, height, hospitalization status, hepatitis
C, HCC, complications of portal hypertension such as
hepatic encephalopathy and mild ascites, listing for
combined liver-kidney transplantation, and listing for
combined liver-intestine transplantation are associ-
ated with high DDLT rates.
The acceptance of an organ and the actual receipt
of each DDLT offer constitute a complex process. It
involves collective decision making that depends on
many measured and unmeasured candidate- and do-
nor-related factors, which include but are not limited
to the candidate’s clinical condition at the time of the
offer, donor availability, donor type, donor-recipient
size matching, and so forth. It is plausible that physi-
cian judgment, donor factors, and unmeasured candi-
date factors resulted in higher DDLT rates for those
listed for combined liver-kidney transplantation or
combined liver-intestine transplantation, and hospi-
talized candidates had higher DDLT rates despite
stratification by the allocation MELD score.
Although the allocation MELD score (urgency) was
still the major determinant of DDLT rates in the
United States, there was a great deal of variation in
the distribution of DDLT rates at a given MELD score.
This variation reflects the significant contribution of
additional candidate factors that result in the actual
acceptance of an offer and receipt of DDLT and is
consistent with physician judgment. We found that
DDLT rates did not increase monotonically with the
allocation MELD score after adjustments for the DSA,
blood type, and intestine policy. There was a steady
increase in the DDLT rates from a MELD score of 15
to a MELD score of 32. However, there appeared to be
little increase in DDLT rates from a MELD score of 32
to a MELD score of 40, even though the risk of
wait-list death has previously been shown to increase
dramatically across this range.
Our study showed that high serum creatinine levels
and the receipt of dialysis (components of the MELD
score) were associated with lower DDLT rates in the
MELD era. We have previously demonstrated that at a
given MELD score, every unit increase in serum
Figure 2. MELD score–specific box-whisker plots of DDLT HRs. The HRs were estimated with a model stratified by the MELD score,
DSA, blood type, and intestine listing policy. Candidate-specific HRs were estimated with all remaining covariates and were scaled by
their MELD score–specific means so that they averaged to 1. For each MELD score, the box represents the 75th and 25th percentiles,
whereas the whiskers denote the 95th and 5th percentiles. The line in the middle of each box denotes the median, which tends to be
very close to 1 because the HRs within each MELD score were scaled so that they averaged to 1. If the MELD score were the only
factor (other than the DSA, blood type, and liver-intestine policy) to affect DDLT rates, there would be no distribution of HRs; with a
given MELD score, each candidate would have the same predicted DDLT rate, which would equal 1 after scaling. The whiskers for
each MELD score–specific distribution of HRs reflect the systematic heterogeneity in DDLT rates due to various candidate factors.
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creatinine is associated with lower wait-list mortality.
The association of lower DDLT rates with high creati-
nine levels at a given MELD score in the current study
demonstrates the evidence-based clinical practice of
allocating scarce resources to the sickest first. How-
ever, the negative effect of creatinine on DDLT rates
was ameliorated by the increase in height. Candidates
on dialysis at the time of transplantation overall have
a significant but lower survival benefit from DDLT in
comparison with their counterparts not on dialysis at
a given MELD score.9,13 This perception of a lower but
significant survival benefit associated with dialysis at
a given MELD score may affect clinical practice and
result in lower DDLT rates for such candidates.
The current study confirms the association of lower
DDLT rates with female sex.6,7,9,10,17 It has been
speculated that lower DDLT rates among females ver-
sus males could be due to lower creatinine levels (a
MELD covariate) and/or recipient size mismatching.
To tease out why females had lower DDLT rates, we
looked at the interactions between female sex and cre-
atinine and between female sex and height; however,
neither of these interactions was significant, and this
suggests that the lower DDLT rates among females at
a given MELD score are not affected by creatinine or
height.
Even though the time at risk ended with the grant-
ing of an exception MELD score, candidates with HCC
had higher DDLT rates than others. Because MELD
exceptions were applied to candidates with stage T1
or T2 HCC before July 1, 2005 and to candidates with
stage T2 HCC after July 1, 2005, the HCC candidates
examined in our study had either stage T1 HCC (after
July 2005) or stage T3 HCC (beyond the Milan crite-
ria), did not receive an exception, and underwent
transplantation with their laboratory MELD scores.
We speculate that such candidates may undergo
DDLT using marginal and high-risk donor organs,
and this might be driving the higher DDLT rates
among HCC candidates.
One of the goals of the MELD-based allocation and
distribution policy was to provide transplantation to
the sickest candidates first. The higher DDLT rates
among hospitalized candidates in ICU and non-ICU
settings versus nonhospitalized candidates suggest
that MELD-based allocation has done fairly well in
this regard. Our current study and previous stud-
ies12,19,20 evaluating the effectiveness of the MELD-
based allocation policy have provided evidence that
the current allocation policy is meeting its goal of bal-
ancing the needs of the most medically urgent candi-
dates against the practical limitations of extensive
sharing across large geographic areas.
The main limitations of this study are its retrospec-
tive, observational design and associated problems
that may have affected the results, such as a selection
bias, an inability to assess the effects of unmeasured
candidate characteristics, and missing data for some
candidate-level variables. The grading of ascites and
hepatic encephalopathy was based on program
reporting using subjective definitions and may have
been subject to misclassification. Despite these limita-
tions, our results show that DDLT rates among active
candidates are affected by many candidate factors
other than the DSA and the allocation MELD score.
Furthermore, had our covariates been measured more
precisely and been subject to less error, we would
have had greater statistical power, and perhaps addi-
tional significant findings would have emerged.
In conclusion, under the current allocation rules,
the MELD score and the DSA are the most important
determinants of DDLT rates, but other measured can-
didate characteristics are systematically affecting
which candidates do or do not undergo DDLT within
the same DSA, with the blood type, and with the
same MELD score.
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